Evidence map›Paper›PMID 32787269›Full record

ArticleMolecular pharmaceutics2020

Addressing the Biochemical Foundations of a Glucose-Based "Trojan Horse"-Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to

Jelena Matović, Juulia Järvinen, Helena C Bland, Iris K Sokka, Surachet Imlimthan, Ruth Mateu Ferrando, Kristiina M Huttunen, Juri Timonen, Sirpa Peräniemi, Olli Aitio and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Quantification ofMedicinal research reviews · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Synthesis andACS omega · 2022
    Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jelena MatovićDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.
Juulia JärvinenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.
Helena C BlandDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.
Iris K SokkaDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0002-5148-4987
Surachet ImlimthanDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0003-2520-2146
Ruth Mateu FerrandoDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.
Kristiina M HuttunenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.ORCID 0000-0002-1175-8517
Juri TimonenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.ORCID 0000-0001-7720-2215
Sirpa PeräniemiSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.
Olli AitioGlykos Finland Ltd., Viikinkaari 6, FI-00790 Helsinki, Finland.
Anu J AiraksinenDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0002-5943-3105
Mirkka SarparantaDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0002-2956-4366
Mikael P JohanssonDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0002-9793-8235
Jarkko RautioSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.
Filip S EkholmDepartment of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland.ORCID 0000-0002-4461-2215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT) for cancer is on the rise worldwide due to recent developments of in-hospital neutron accelerators which are expected to revolutionize patient treatments. There is an urgent need for improved boron delivery agents, and herein we have focused on studying the biochemical foundations upon which a successful GLUT1-targeting strategy to BNCT could be based. By combining synthesis and molecular modeling with affinity and cytotoxicity studies, we unravel the mechanisms behind the considerable potential of appropriately designed glucoconjugates as boron delivery agents for BNCT. In addition to addressing the biochemical premises of the approach in detail, we report on a hit glucoconjugate which displays good cytocompatibility, aqueous solubility, high transporter affinity, and, crucially, an exceptional boron delivery capacity in the

Indexed as

BoronBoron Neutron Capture TherapyCell Line, TumorDrug CarriersDrug LiberationGlucoseGlucose Transporter Type 1HumansIsotopesMolecular Docking SimulationNeoplasmsBoronBoron-10Drug CarriersGlucoseGlucose Transporter Type 1IsotopesSLC2A1 protein, humanboron neutron capture therapycancer therapeuticscarbohydratesdrug deliveryglucose transportersmedicinal chemistry

Identifiers

PMID32787269
PMCPMC7539299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.